Sichuan Biokin PharmaceuticalLtd Past Earnings Performance
Past criteria checks 4/6
Sichuan Biokin PharmaceuticalLtd has been growing earnings at an average annual rate of 56.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 42.4% per year. Sichuan Biokin PharmaceuticalLtd's return on equity is 89.6%, and it has net margins of 65%.
Key information
56.4%
Earnings growth rate
55.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 42.4% |
| Return on equity | 89.6% |
| Net Margin | 65.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sichuan Biokin PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 5,847 | 3,800 | 371 | 1,168 |
| 30 Jun 24 | 5,804 | 4,214 | 343 | 958 |
| 31 Mar 24 | 5,901 | 4,391 | 364 | 836 |
| 31 Dec 23 | 562 | -780 | 361 | 746 |
| 30 Sep 23 | 601 | -555 | 383 | 601 |
| 30 Jun 23 | 710 | -473 | 420 | 535 |
| 31 Mar 23 | 705 | -404 | 421 | 463 |
| 31 Dec 22 | 703 | -282 | 411 | 375 |
| 30 Sep 22 | 663 | -320 | 396 | 385 |
| 31 Dec 21 | 797 | -100 | 465 | 279 |
| 31 Dec 20 | 1,013 | 38 | 635 | 196 |
| 31 Dec 19 | 1,207 | 8 | 827 | 181 |
| 31 Dec 14 | 418 | 17 | 224 | 0 |
| 31 Dec 13 | 415 | 35 | 213 | 0 |
Quality Earnings: 688506 has high quality earnings.
Growing Profit Margin: 688506 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688506's earnings have grown significantly by 56.4% per year over the past 5 years.
Accelerating Growth: 688506 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 688506 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).
Return on Equity
High ROE: 688506's Return on Equity (89.6%) is considered outstanding.